The shares of Sudeep Pharma listed on the NSE and BSE today, debuting at a premium of 24% on Dalal Street. The price band of the issue is set between Rs 563-593 per share.
| Sudeep Pharma IPO | Key Details |
| Price band | Rs 563-593 per share |
| Subscription | 93.71 times |
| GMP | 20.40% |
| IPO Allotment date | November 26 |
| Listing date | November 28 |
Sudeep Pharma IPO: Key details
Sudeep Pharma raised Rs 895 crores via a mix of fresh issue and an offer for sale. The IPO consisted of 0.16 crore fresh shares of Rs 95 crores and an offer for sale of 1.35 crore shares worth Rs 800 crores. The IPO was opened for bidding on November 21 and ended on November 25. The allotment was finalised on November 26.
Sudeep Pharma IPO: Book manager and registrar
ICICI Securities worked as the book-running lead manager for the IPO, and MUFG Intime India was the registrar of the issue.
About Sudeep Pharma
Sudeep Pharma, established in 1989, is a technology-led manufacturer of excipients and speciality ingredients serving the pharmaceutical, food, and nutrition industries. It has a global footprint spanning from the U.S. to South America to Europe, the Middle East, Africa, and Asia-Pacific. The company operates three manufacturing facilities in Vadodara, Gujarat, and, following its acquisition of NSS( Nutrition Supplies and Services) in 2025, an additional facility in Ireland.
Sudeep Pharma Share Price, IPO Listing LIVE: Check here Live Coverage on Sudeep Pharma IPO Listing, GMP, Share Price, Price Band, Review
Sudeep Pharma Share Price, IPO Listing, GMP Live: Share performance post-listing
Sudeep Pharma shares continue to trade in the green. The stock is quoting at Rs 749.45 on the BSE, up Rs 15.50 or 2.11%, while on the NSE, it is trading at Rs 757.55, gaining Rs 27.55 or 3.77%.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Sudeep Pharma makes a strong debut on Dalal Street
Sudeep Pharma shares began trading on the stock exchanges with a strong listing premium today. The stock opened at Rs 733.95 on the BSE and Rs 730 on the NSE, compared to its issue price of Rs 593, translating to a listing gain of 23.8% on the BSE and 23.1% on the NSE.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Key financial metrics
For FY25, Sudeep Pharma reported revenue of Rs 501.9 crore, supported by strong margins across operating levels. The company posted a return on net worth of 27.88% and maintained PAT margins above 27%.
Sudeep Pharma Share Price, IPO Listing, GMP Live: International business
Sudeep Pharma serves over 1,100 customers spread across around 100 countries. The company’s largest export markets are in the USA, Europe, APAC and Africa regions. As of June 2025, the export sales accounted for 58.68% of the revenue from operations. The company has served over 1,100 global customers across pharma, food, nutrition, and FMCG sectors, including marquee names like Pfizer, Merck, and Danone.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Subscription trends
The IPO saw a strong demand, closing at 93.71 times overall subscription. Retail investors subscribed 15.65 times, non-institutional investors put in bids worth 116.72 times their quota, and the QIB category saw the heaviest response at 213.08 times.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Business operations
The company operate in two business verticals, pharmaceutical, food and nutrition, and speciality ingredients, comprising a portfolio of more than 100 products, including excipients, APIs, mineral actives and speciality ingredients and formulations with brands, such as Presscal, Pressmag, Lubriprez, A-comprez, Novelcap, Lipoboost and Cuvamix.
Sudeep Pharma Share Price, IPO Listing, GMP Live: IPO size and structure
Sudeep Pharma’s IPO combines a Rs 95 crore fresh issue with a much larger Rs 800 crore offer for sale, making it mostly an exit route for existing shareholders. Only a small portion of the proceeds will actually go to the company for business expansion, while the bulk represents promoter and investor stake dilution.
Pharma and nutraceutical ingredients face strict certification norms, where any non-compliance can immediately halt exports and disrupt business operations. With three manufacturing units and one R&D facility concentrated in Vadodara, Gujarat, any regional disruptions could potentially affect Sudeep Pharma’s operational continuity.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Objectives of fresh issue
The offer comprises a fresh issue of Rs 95 crore and an offer for sale (OFS) of Rs 800 crore. The net proceeds will be used for capital expenditure towards the procurement of machinery for the production line located at Nandesari Facility I ( Rs 75.8 crore), and the remaining amount for general corporate purposes.
Sudeep Pharma Share Price, IPO Listing, GMP Live: Industry outlook
The global pharmaceutical excipients and speciality food ingredients markets together are projected to grow steadily, with excipients rising from $10.4 billion in 2024 to about $13 billion by 2029 (CAGR 4.7%), and speciality food ingredients expanding from $85 billion in 2024 to $118 billion by 2029 (CAGR 6.8%).
Sudeep Pharma Share Price, IPO Listing, GMP Live: About the company
Sudeep Pharma is a manufacturer of pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients serving over 100 countries. The company operates six manufacturing facilities with a combined production capacity of 50,000 MT, specialising in minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. The company supplies more than 200 products to a diverse customer base across the pharma, food, and nutrition sectors